What is eTheRNA?
Founded in 2013, eTheRNA operates at the intersection of advanced molecular biology and clinical medicine. The company leverages its unique mRNA platform to develop therapeutic interventions that modulate the immune system, positioning itself as a key player in the next generation of precision medicine. By focusing on both cancer and infectious diseases, eTheRNA addresses critical unmet medical needs, utilizing its technological infrastructure to drive innovation in therapeutic delivery and efficacy. The firm's strategic positioning within the European biotech ecosystem has allowed it to attract high-caliber investment, facilitating the transition from early-stage research to sophisticated clinical development.
How much funding has eTheRNA raised?
eTheRNA has raised a total of $103.7M across 2 funding rounds:
Series A
$26.7M
Series B
$77M
Series A (2016): $26.7M with participation from Life Sciences Partners, Omega Funds, Boehringer Ingelheim, Fund+ NV/SA, and PMV
Series B (2022): $77M led by Omega Fund Management, Boehringer Ingelheim, PMV, Novalis LifeSciences, Life Sciences Partners, Fund+ NV/SA, and Professor Kenneth Chien
Key Investors in eTheRNA
Boehringer Ingelheim
A research-driven pharmaceutical giant with a global footprint, focusing on human pharma, animal health, and biopharmaceutical manufacturing.
PMV
A strategic financial partner supporting the growth of innovative SMEs and infrastructure projects within the Flanders region.
Fund+ NV/SA
An open-ended investment fund dedicated to fostering long-term equity growth in the Belgian life sciences sector.
What's next for eTheRNA?
With the infusion of capital from its latest financing round, eTheRNA is well-positioned to accelerate its clinical pipeline and expand its research capabilities. The company is expected to prioritize the advancement of its lead candidates through rigorous human trials, while simultaneously refining its mRNA delivery mechanisms. As the biotech sector continues to emphasize the scalability of nucleic acid-based therapies, eTheRNA's focus on sustainable, long-term value creation will likely involve strategic partnerships and potential expansion into new therapeutic indications. The ongoing support from its diverse investor base provides the necessary runway to navigate the complexities of late-stage clinical development and regulatory approval processes.
See full eTheRNA company page
